Alto Neuroscience Posts Q2 Net Loss
Alto Neuroscience (NYSE:ANRO), a clinical-stage biotechnology company focused on precision psychiatry, released its second-quarter results on August 13, 2025. It reported a net loss of $17.7 million, translating to earnings per share (EPS) of $(0.65) (GAAP). Operating expenses were stable for research and development, while general and administrative costs showed a modest rise. Management highlighted a cash position of $148.1 million at the end of Q2 2025, stating that this will support planned activities and four major clinical study readouts into 2028, underscoring prudent expense control and a stable, if loss-making, quarter for the business.
Source: Analyst estimates for the quarter provided by FactSet.
Alto Neuroscience develops targeted therapies for central nervous system (CNS) disorders, using its proprietary precision psychiatry platform. This platform integrates neurocognitive assessments, electroencephalogram (EEG) data, wearable devices, and genetic information. Through machine learning, it identifies biomarkers—measurable indicators—linked to psychiatric conditions and potential drug response.
Source Fool.com
